 "Dr Reddy's gains on receiving EIR for Miryalaguda plant")
Dr Reddy’s Laboratories was up nearly 3% to Rs 2,698 on the BSE in intra-day trade after the company said it has received Establishment Inspection Report (EIR) from the US health regulator for its Miryalaguda plant.
“We have received EIR from US Food and Drug Administration (US FDA) for its active pharmaceutical plant (API) at Miryalaguda indicating the successful closure of the agency's audit,” Dr Reddy’s Laboratories said in a statement.
The plant, which was inspected by USFDA from February 13-21’2017, had received Form 483 with three observations from USFDA.
“Miryalaguda plant supplies active ingredients for company’s captive consumption as well as for its customers. The news is positive, however given the valuations, we are NEUTRAL on the stock,” Sarabjit Kour Nangra, VP Research- Pharma, Angel Broking.
At 01:35 pm; the stock was trading 2% higher at Rs 2,675 on BSE against 0.09% rise in the S&P BSE Sensex. A combined 637,537 shares changed hands on the counter on BSE and NSE.
“We have received EIR from US Food and Drug Administration (US FDA) for its active pharmaceutical plant (API) at Miryalaguda indicating the successful closure of the agency's audit,” Dr Reddy’s Laboratories said in a statement.
The plant, which was inspected by USFDA from February 13-21’2017, had received Form 483 with three observations from USFDA.
“Miryalaguda plant supplies active ingredients for company’s captive consumption as well as for its customers. The news is positive, however given the valuations, we are NEUTRAL on the stock,” Sarabjit Kour Nangra, VP Research- Pharma, Angel Broking.
At 01:35 pm; the stock was trading 2% higher at Rs 2,675 on BSE against 0.09% rise in the S&P BSE Sensex. A combined 637,537 shares changed hands on the counter on BSE and NSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%